I think a big part of that comes down to regulation when it comes to biotech, which, frankly, I think is a good thing. After all, skimping on software (usually) won’t kill anyone, but imagine how much worse things could have been with something like Theranos absent regulation.¹
⸻
1. For those rushing to point out that regulation didn’t stop Theranos, it might not have kept the fraud from starting, but it did keep it from continuing.
Pointing out Theranos would be like pointing out the existence of double agents despite rigorous counter-measures. Things will happen; one wants them to happen less.
⸻
1. For those rushing to point out that regulation didn’t stop Theranos, it might not have kept the fraud from starting, but it did keep it from continuing.